Nektar Therapeutics (NKTR) shareholders
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Samlyn Capital, LLC Joint filing with Samlyn, LP (5.20%), Robert Pohly (5.20%) | 9,667,048 | 5.20% | 13G (passive) | Dec 31, 2024 |
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 4,303,188 | 15.00% | 13G (passive) amendment | Mar 31, 2026 |
| Sina Toussi Joint filing with Two Seas Capital LP (9.80%), Two Seas Capital GP LLC (9.80%) | 3,345,978 | 9.80% | 13G (passive) amendment | Sep 25, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (11.10%) | 3,036,761 | 11.10% | 13G (passive) | Feb 27, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.80%), Lampert Mark N (9.80%) and 3 more | 2,852,698 | 9.80% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 2,643,796 | 7.80% | 13G (passive) | Jun 30, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (7.10%), Bvf Inc/Il (7.10%) and 1 more | 2,391,075 | 7.10% | 13G (passive) amendment | Jun 30, 2026 |
| Two Seas Capital LP Joint filing with Two Seas Capital GP LLC (6.80%), Sina Toussi (6.80%) | 1,959,178 | 6.80% | 13G (passive) | Mar 31, 2026 |
| TCG Crossover Fund II, L.P. Joint filing with TCG Crossover GP II, LLC (9.30%), Chen Yu (9.30%) | 1,933,333 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
| State Street Corporation | 1,772,302 | 5.20% | 13G (passive) | Sep 30, 2026 |
| Vanguard Capital Management | 1,747,653 | 5.17% | 13G (passive) | Jun 30, 2026 |
| Susquehanna Portfolio Strategies, LLC Joint filing with Susquehanna Securities, LLC (6.30%) | 1,235,864 | 6.30% | 13G (passive) | Sep 30, 2025 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.40%), Israel A. Englander (5.40%) | 932,863 | 5.40% | 13G (passive) | Jun 27, 2025 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (5.72%), Wilmot B. Harkey (5.72%) | 709,761 | 5.72% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NKTR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 5,067,920 | 14.84% | $353.79M | +764,732 | 0.02% |
| Two Seas Capital LP | 3,092,234 | 9.06% | $215.87M | +1,133,056 | 4.28% |
| BlackRock, Inc. | 2,941,851 | 8.62% | $205.37M | +2,249,201 | 0.00% |
| Bvf Inc/Il | 2,391,075 | 7.00% | $166.92M | −168,520 | 4.27% |
| Vanguard Capital Management LLC | 1,496,849 | 4.38% | $104.50M | +299,794 | 0.00% |
| Two Sigma Investments, LP | 1,202,004 | 3.52% | $83.91M | +271,263 | 0.06% |
| Vestal Point Capital, LP | 1,000,000 | 2.93% | $69.81M | +715,000 | 1.63% |
| Morgan Stanley | 936,560 | 2.74% | $65.38M | +277,173 | 0.00% |
| State Street Corp | 909,679 | 2.66% | $63.50M | +664,952 | 0.00% |
| Geode Capital Management, LLC | 881,306 | 2.58% | $61.54M | +534,511 | 0.00% |
| Prosight Management, LP | 810,000 | 2.37% | $56.55M | +75,000 | 9.74% |
| Armistice Capital, LLC | 724,000 | 2.12% | $50.54M | +146,000 | 0.62% |
| Gilder Gagnon Howe & Co LLC | 600,873 | 1.76% | $41.95M | +329,115 | 0.43% |
| Millennium Management LLC | 478,120 | 1.40% | $33.38M | +73,843 | 0.01% |
| Braidwell LP | 473,617 | 1.39% | $33.06M | +250,916 | 1.22% |
| Sofinnova Investments, Inc. | 471,763 | 1.38% | $32.93M | −37,783 | 1.70% |
| Woodline Partners LP | 470,875 | 1.38% | $32.87M | +55,540 | 0.10% |
| Orbimed Advisors LLC | 465,346 | 1.36% | $32.49M | +190,346 | 0.60% |
| UBS Group AG | 428,400 | 1.25% | $29.91M | +108,228 | 0.00% |
| Emerald Advisers, LLC | 390,158 | 1.14% | $27.24M | −4,446 | 0.64% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 239 | 36M | 100.0% | 75 / 100 | 41 / 40 | 13M | 3M |
| Q1 2026 | 207 | 27M | 78.2% | 69 / 73 | 46 / 30 | 14M | 3M |
| Q4 2025 | 172 | 17M | 50.7% | 61 / 48 | 42 / 31 | 7M | 4M |
| Q3 2025 | 145 | 14M | 42.2% | 64 / 41 | 26 / 19 | 9M | 3M |
| Q2 2025 | 101 | 8M | 22.4% | 101 / 0 | 0 / 0 | 8M | 0M |
| Q2 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2023 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2022 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2021 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
131 funds held NKTR in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NKTR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,834,001 | 5.37% | $118.99M | 0.12% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,075,108 | 3.15% | $75.05M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 896,117 | 2.62% | $62.56M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 492,779 | 1.44% | $31.97M | 0.12% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 419,823 | 1.23% | $27.24M | 0.11% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 387,571 | 1.14% | $27.06M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 376,892 | 1.10% | $26.63M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 285,292 | 0.84% | $19.92M | 0.13% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 172,419 | 0.50% | $12.18M | 0.16% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 162,987 | 0.48% | $10.57M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 151,830 | 0.44% | $9.85M | 0.04% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 115,142 | 0.34% | $8.04M | 1.88% | Jun 30, 2026 |
| Emerald Growth Fund | 104,721 | 0.31% | $7.40M | 0.50% | Jul 31, 2026 |
| Emerald Growth Fund | 104,721 | 0.31% | $8.91M | 0.63% | Apr 30, 2026 |
| SmallCap Growth Fund I | 92,975 | 0.27% | $6.57M | 0.26% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Howard W. Robin | President & CEO, Director | 54,655 | 0.16% | Aug 20, 2026 |
| Jonathan Zalevsky | Chief R&D Officer | 9,570 | 0.03% | Aug 20, 2026 |
| Linda M. Rubinstein | Interim CFO | – | – | May 26, 2026 |
| Mark Andrew Wilson | Chief Legal Officer | 21,585 | 0.06% | Nov 25, 2025 |
| Roy A. Whitfield | Director | 21,185 | 0.06% | Sep 25, 2026 |
| Robert Chess | Director | 19,299 | 0.06% | Sep 25, 2026 |
| Diana Brainard | Director | 3,904 | 0.01% | Sep 25, 2026 |
| Jeffrey Robert Ajer | Director | 4,277 | 0.01% | Sep 25, 2026 |
| R. Scott Greer | Director | 22,239 | 0.07% | Sep 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Chess Director | Sep 23, 2026 | Award | +2,000 | – | – | 19,019 |
| R. Scott Greer Director | Sep 23, 2026 | Award | +2,000 | – | – | 22,239 |
| Jeffrey Robert Ajer Director | Sep 23, 2026 | Award | +2,000 | – | – | 4,277 |
| Diana Brainard Director | Sep 23, 2026 | Award | +2,000 | – | – | 3,904 |
| Roy A. Whitfield Director | Sep 23, 2026 | Award | +2,000 | – | – | 16,417 |
| Jonathan Zalevsky Chief R&D Officer | Aug 18, 2026 | Sale | −186 | $71.98 | $13.39K | 9,570 |
| Howard W. Robin President & CEO, Director | Aug 18, 2026 | Sale | −418 | $71.98 | $30.09K | 54,627 |
| Jonathan Zalevsky Chief R&D Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −5,681 | $70.00 | $397.67K | 9,756 |
| Howard W. Robin President & CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −4,500 | $61.65 | $277.43K | 55,045 |
| Howard W. Robin President & CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,500 | $60.81 | $334.46K | 59,545 |
| Howard W. Robin President & CEO, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −4,697 | $60.71 | $285.15K | 65,045 |
| Howard W. Robin President & CEO, Director | Jun 16, 2026 | Sale(10b5-1 plan) | −5,303 | $59.97 | $318.02K | 69,742 |
| Jonathan Zalevsky Chief R&D Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −5,538 | $60.71 | $336.21K | 15,437 |
| Jonathan Zalevsky Chief R&D Officer | May 19, 2026 | Sale | −199 | $65.51 | $13.04K | 20,975 |
| Howard W. Robin President & CEO, Director | May 19, 2026 | Sale | −444 | $65.51 | $29.09K | 75,045 |
| Jonathan Zalevsky Chief R&D Officer | Feb 18, 2026 | Sale | −180 | $73.00 | $13.14K | 21,174 |
| Howard W. Robin President & CEO, Director | Feb 18, 2026 | Sale | −423 | $73.00 | $30.88K | 75,489 |
| Jonathan Zalevsky Chief R&D Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −3,867 | $35.67 | $137.94K | 21,354 |
| Jonathan Zalevsky Chief R&D Officer | Dec 22, 2025 | Award | +6,250 | – | – | 25,221 |
| Howard W. Robin President & CEO, Director | Dec 22, 2025 | Award | +21,667 | – | – | 75,912 |
| Jonathan Zalevsky Chief R&D Officer | Nov 25, 2025 | Sale | −1,157 | $54.28 | $62.80K | 18,971 |
| Howard W. Robin President & CEO, Director | Nov 25, 2025 | Sale | −2,207 | $54.28 | $119.80K | 54,245 |
| Mark Andrew Wilson Chief Legal Officer | Nov 25, 2025 | Sale | −630 | $54.28 | $34.20K | 21,585 |
| Jonathan Zalevsky Chief R&D Officer | Nov 21, 2025 | Award | +2,666 | – | – | 20,128 |
| Howard W. Robin President & CEO, Director | Nov 21, 2025 | Award | +7,110 | – | – | 56,452 |
| Mark Andrew Wilson Chief Legal Officer | Nov 21, 2025 | Award | +1,903 | – | – | 22,215 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −1,210 | $48.18 | $58.30K | 49,342 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −2,156 | $47.49 | $102.39K | 50,552 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −1,200 | $46.41 | $55.69K | 52,708 |
| Howard W. Robin President & CEO, Director | Sep 9, 2025 | Sale(10b5-1 plan) | −2,100 | $45.16 | $94.84K | 53,908 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −1,136 | $39.89 | $45.32K | 56,008 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −2,226 | $38.82 | $86.41K | 57,144 |
| Howard W. Robin President & CEO, Director | Sep 5, 2025 | Sale(10b5-1 plan) | −3,304 | $37.87 | $125.12K | 59,370 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,134 | $35.80 | $40.60K | 62,674 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −613 | $34.40 | $21.09K | 63,808 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,496 | $33.54 | $50.18K | 64,421 |
| Howard W. Robin President & CEO, Director | Sep 4, 2025 | Sale(10b5-1 plan) | −1,923 | $32.37 | $62.25K | 65,917 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −432 | $33.60 | $14.52K | 17,958 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −793 | $32.43 | $25.72K | 18,390 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −189 | $34.41 | $6.50K | 17,769 |
| Jonathan Zalevsky Chief R&D Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −307 | $35.69 | $10.96K | 17,462 |
| Howard W. Robin President & CEO, Director | Sep 2, 2025 | Sale(10b5-1 plan) | −1,500 | $30.16 | $45.24K | 67,840 |
| Jonathan Zalevsky Chief R&D Officer | Sep 2, 2025 | Sale(10b5-1 plan) | −485 | $30.10 | $14.60K | 19,183 |
| Howard W. Robin President & CEO, Director | Aug 19, 2025 | Sale | −1,573 | $26.59 | $41.83K | 69,340 |
| Mark Andrew Wilson Chief Legal Officer | Aug 19, 2025 | Sale | −676 | $26.59 | $17.97K | 20,312 |
| Jonathan Zalevsky Chief R&D Officer | Aug 19, 2025 | Sale | −725 | $26.59 | $19.28K | 19,668 |
| Jonathan Zalevsky Chief R&D Officer | May 19, 2025 | Sale | −10,712 | $0.67 | $7.18K | 305,892 |
| Mark Andrew Wilson Chief Legal Officer | May 19, 2025 | Sale | −9,996 | $0.67 | $6.70K | 314,296 |
| Howard W. Robin President & CEO, Director | May 19, 2025 | Sale | −23,208 | $0.67 | $15.55K | 1,063,693 |
| Howard W. Robin President & CEO, Director | Feb 19, 2025 | Sale | −23,774 | $1.01 | $24.01K | 1,086,901 |
| Jonathan Zalevsky Chief R&D Officer | Feb 19, 2025 | Sale | −10,300 | $1.01 | $10.40K | 316,604 |
| Mark Andrew Wilson Chief Legal Officer | Feb 19, 2025 | Sale | −11,040 | $1.01 | $11.15K | 324,292 |
| Mark Andrew Wilson Chief Legal Officer | Dec 24, 2024 | Sale | −16,560 | $0.89 | $14.74K | 335,332 |
| Mark Andrew Wilson Chief Legal Officer | Dec 23, 2024 | Sale | −33,402 | $0.90 | $30.06K | 351,892 |
| Jonathan Zalevsky Chief R&D Officer | Dec 19, 2024 | Sale | −51,115 | $0.94 | $48.05K | 326,904 |
| Howard W. Robin President & CEO, Director | Dec 18, 2024 | Sale | −85,035 | $0.99 | $84.18K | 1,110,675 |
| Howard W. Robin President & CEO, Director | Dec 17, 2024 | Sale | −46,995 | $1.01 | $47.46K | 1,195,710 |
| Howard W. Robin President & CEO, Director | Dec 13, 2024 | Award | +410,625 | – | – | 1,242,705 |
| Mark Andrew Wilson Chief Legal Officer | Dec 13, 2024 | Award | +165,938 | – | – | 385,294 |
| Jonathan Zalevsky Chief R&D Officer | Dec 13, 2024 | Award | +135,000 | – | – | 378,019 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nektar Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 165,383 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Howard W. Robin Officer, Director | Aug 18, 2026 | 418 | $30.09K | Aug 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Aug 18, 2026 | 186 | $13.39K | Aug 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Jun 30, 2026 | 5,681 | $371.48K | Jun 30, 2026 | Restricted Stock Units |
| Howard W. Robin Officer, Director | Jun 17, 2026 | 10,000 | $602.70K | Jun 17, 2026 | Restricted Stock Vesting |
| Howard W. Robin Officer, Director | Jun 16, 2026 | 10,000 | $609.60K | Jun 16, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Jun 15, 2026 | 5,538 | $328.85K | Jun 15, 2026 | Restricted Stock Units |
| Howard W. Robin Officer, Director | May 19, 2026 | 444 | $29.08K | May 19, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | May 19, 2026 | 199 | $13.04K | May 19, 2026 | Restricted Stock Vesting |
| Mark Andrew Wilson Former Officer | Mar 13, 2026 | 78,510 | $5.70M | Mar 13, 2026 | Option Granted - 12/13/2023 |
| Howard W. Robin Officer, Director | Feb 18, 2026 | 423 | $30.88K | Feb 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Feb 18, 2026 | 180 | $13.14K | Feb 18, 2026 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Jan 20, 2026 | 3,867 | $137.95K | Jan 20, 2026 | Restricted Stock Vesting |
| Howard W. Robin Officer, Director | Nov 25, 2025 | 2,207 | $129.81K | Nov 25, 2025 | Restricted Stock Vesting |
| Mark Andrew Wilson Officer | Nov 25, 2025 | 630 | $37.06K | Nov 25, 2025 | Restricted Stock Vesting |
| Jonathan Zalevsky Officer | Nov 25, 2025 | 1,157 | $68.05K | Nov 25, 2025 | Restricted Stock Vesting |
Congress trades
2 trades in Nektar Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Josh Gottheimer NJ05 · joint account | Sold | Jun 21, 2018 | $1K–15K | Oct 2, 2018 103 days late |
| Josh Gottheimer NJ05 · joint account | Bought | Jun 6, 2018 | $1K–15K | Oct 2, 2018 118 days late |
See a number that looks wrong?